Literature DB >> 23272912

Hitting the golden TORget: curcumin's effects on mTOR signaling.

Christopher S Beevers1, Hongyu Zhou, Shile Huang.   

Abstract

The polyphenol natural product curcumin possesses a plethora of biological and pharmacological properties. For years, much interest has been placed in the development and use of curcumin and its derivatives for the prevention and treatment of cardiovascular, diabetic, and neurodegenerative diseases, as well as cancer. Increasing evidence suggests that curcumin displays amazing molecular versatility, and the number of its proposed cellular targets grows as the research continues. The mammalian target of rapamycin (mTOR) is a master kinase, regulating cell growth/proliferation, survival, and motility. Dysregulated mTOR signaling occurs frequently in cancer, and targeting mTOR signaling is a promising strategy for cancer therapy. Recent studies have identified mTOR as a novel target of curcumin. Here we focus on reviewing current knowledge regarding the effects of curcumin on mTOR signaling for better understanding the anticancer mechanism of curcumin. The emerging studies of mTOR signaling and clinical studies on curcumin with cancer patients are also discussed here.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23272912      PMCID: PMC3638063          DOI: 10.2174/1871520611313070004

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  99 in total

1.  Downstream of Akt: FoxO3 and mTOR in the regulation of autophagy in skeletal muscle.

Authors:  Cristina Mammucari; Stefano Schiaffino; Marco Sandri
Journal:  Autophagy       Date:  2008-03-13       Impact factor: 16.016

Review 2.  Bioavailability of curcumin: problems and promises.

Authors:  Preetha Anand; Ajaikumar B Kunnumakkara; Robert A Newman; Bharat B Aggarwal
Journal:  Mol Pharm       Date:  2007-11-14       Impact factor: 4.939

Review 3.  The biology behind mTOR inhibition in sarcoma.

Authors:  Xiaolin Wan; Lee J Helman
Journal:  Oncologist       Date:  2007-08

4.  The mTOR target 4E-BP1 contributes to differential protein expression during normoxia and hypoxia through changes in mRNA translation efficiency.

Authors:  Michaël G Magagnin; Twan van den Beucken; Kjell Sergeant; Philippe Lambin; Marianne Koritzinsky; Bart Devreese; Bradly G Wouters
Journal:  Proteomics       Date:  2008-03       Impact factor: 3.984

5.  Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin-induced autophagy.

Authors:  Naoki Shinojima; Tomohisa Yokoyama; Yasuko Kondo; Seiji Kondo
Journal:  Autophagy       Date:  2007-08-21       Impact factor: 16.016

Review 6.  Curcumin: from ancient medicine to current clinical trials.

Authors:  H Hatcher; R Planalp; J Cho; F M Torti; S V Torti
Journal:  Cell Mol Life Sci       Date:  2008-06       Impact factor: 9.261

7.  Identification of Protor as a novel Rictor-binding component of mTOR complex-2.

Authors:  Laura R Pearce; Xu Huang; Jérôme Boudeau; Rafał Pawłowski; Stephan Wullschleger; Maria Deak; Adel F M Ibrahim; Robert Gourlay; Mark A Magnuson; Dario R Alessi
Journal:  Biochem J       Date:  2007-08-01       Impact factor: 3.857

8.  Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling.

Authors:  Maurice Phillip DeYoung; Peter Horak; Avi Sofer; Dennis Sgroi; Leif W Ellisen
Journal:  Genes Dev       Date:  2008-01-15       Impact factor: 11.361

9.  PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis.

Authors:  Kathrin Thedieck; Pazit Polak; Man Lyang Kim; Klaus D Molle; Adiel Cohen; Paul Jenö; Cécile Arrieumerlou; Michael N Hall
Journal:  PLoS One       Date:  2007-11-21       Impact factor: 3.240

10.  eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy.

Authors:  Francisco Ramírez-Valle; Steve Braunstein; Jiri Zavadil; Silvia C Formenti; Robert J Schneider
Journal:  J Cell Biol       Date:  2008-04-21       Impact factor: 10.539

View more
  18 in total

1.  Inhibition of PI3K/Akt/mTOR signaling by natural products.

Authors:  Shile Huang
Journal:  Anticancer Agents Med Chem       Date:  2013-09       Impact factor: 2.505

2.  Curcumin inhibits cell growth and invasion and induces apoptosis through down-regulation of Skp2 in pancreatic cancer cells.

Authors:  Jingna Su; Xiuxia Zhou; Lixia Wang; Xuyuan Yin; Zhiwei Wang
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

Review 3.  Therapeutic role of targeting mTOR signaling and neuroinflammation in epilepsy.

Authors:  Samantha L Hodges; Joaquin N Lugo
Journal:  Epilepsy Res       Date:  2020-01-30       Impact factor: 2.991

4.  HS-133, a novel fluorescent phosphatidylinositol 3-kinase inhibitor as a potential imaging and anticancer agent for targeted therapy.

Authors:  Ju-Hee Lee; Kyung Hee Jung; Hyunseung Lee; Mi Kwon Son; Sun-Mi Yun; Sung-Hoon Ahn; Kyeong-Ryoon Lee; Soyoung Lee; Donghee Kim; Sungwoo Hong; Soon-Sun Hong
Journal:  Oncotarget       Date:  2014-10-30

5.  Association of cancer metabolism-related proteins with oral carcinogenesis - indications for chemoprevention and metabolic sensitizing of oral squamous cell carcinoma?

Authors:  Martin Grimm; Marcel Cetindis; Max Lehmann; Thorsten Biegner; Adelheid Munz; Peter Teriete; Wiebke Kraut; Siegmar Reinert
Journal:  J Transl Med       Date:  2014-07-21       Impact factor: 5.531

6.  Neuroprotective Effects of Curcumin-Loaded Emulsomes in a Laser Axotomy-Induced CNS Injury Model.

Authors:  Elif Nur Yilmaz; Sadik Bay; Gurkan Ozturk; Mehmet Hikmet Ucisik
Journal:  Int J Nanomedicine       Date:  2020-11-20

7.  In silico and in vitro approaches to evaluate the bioactivity of Cassia auriculata L extracts.

Authors:  Rajagopal Anitha; Rajakannu Subashini; Ponnusamy Senthil Kumar
Journal:  IET Nanobiotechnol       Date:  2020-05       Impact factor: 1.847

Review 8.  Natural products as potential cancer therapy enhancers: A preclinical update.

Authors:  Abed Agbarya; Nili Ruimi; Ron Epelbaum; Eran Ben-Arye; Jamal Mahajna
Journal:  SAGE Open Med       Date:  2014-09-02

9.  Analysis of the anticancer activity of curcuminoids, thiotryptophan and 4-phenoxyphenol derivatives.

Authors:  Shireen Parsai; Rick Keck; Ewa Skrzypczak-Jankun; Jerzy Jankun
Journal:  Oncol Lett       Date:  2013-11-12       Impact factor: 2.967

10.  Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1α signaling.

Authors:  Yuefeng Du; Qingzhi Long; Lin Zhang; Ying Shi; Xioagang Liu; Xudong Li; Bin Guan; Yanchao Tian; Xinyang Wang; Lei Li; Dalin He
Journal:  Int J Oncol       Date:  2015-10-13       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.